Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
RAPP 
Rapport Therapeutics, Inc. Common Stock (RAPP)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
01/09/2026: RAPP (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $52.25
1 Year Target Price $52.25
| 4 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -9.66% | Avg. Invested days 28 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 01/09/2026 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.35B USD | Price to earnings Ratio - | 1Y Target Price 52.25 |
Price to earnings Ratio - | 1Y Target Price 52.25 | ||
Volume (30-day avg) 5 | Beta - | 52 Weeks Range 6.43 - 42.27 | Updated Date 01/9/2026 |
52 Weeks Range 6.43 - 42.27 | Updated Date 01/9/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.27 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -15.89% | Return on Equity (TTM) -23.41% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 848132816 | Price to Sales(TTM) - |
Enterprise Value 848132816 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 47661138 | Shares Floating 30414955 |
Shares Outstanding 47661138 | Shares Floating 30414955 | ||
Percent Insiders 4.7 | Percent Institutions 104.32 |
Upturn AI SWOT
Rapport Therapeutics, Inc. Common Stock
Company Overview
History and Background
Rapport Therapeutics, Inc. was founded in 2015 with a mission to develop precision medicines for neurological and psychiatric disorders. The company went public via an Initial Public Offering (IPO) in February 2023. Key milestones include the progression of its lead drug candidates into clinical trials and strategic partnerships.
Core Business Areas
- Neurological Disorders: Focuses on developing small molecule therapeutics targeting specific neuronal pathways implicated in diseases such as epilepsy, Parkinson's disease, and depression.
- Psychiatric Disorders: Develops treatments for mood disorders and other psychiatric conditions, aiming to address unmet needs with novel mechanisms of action.
Leadership and Structure
Rapport Therapeutics is led by a team of experienced professionals in drug development, neuroscience, and business. The company operates as a biotechnology firm focused on research and development, with a lean organizational structure designed to facilitate rapid advancement of its pipeline.
Top Products and Market Share
Key Offerings
- Product Name 1: RTX-101 (Gaboxadol analog) - Description: A positive allosteric modulator of GABA-A receptors, being developed for specific seizure disorders. Market Share: N/A (Early-stage development). Competitors: Companies developing other GABA-A modulators or novel anti-epileptic drugs.
- Product Name 2: RTX-102 (Experimental compound) - Description: Investigational therapy for Parkinson's disease, targeting specific dopaminergic pathways. Market Share: N/A (Pre-clinical/Early clinical). Competitors: Companies developing Parkinson's disease treatments, including levodopa alternatives and neuroprotective agents.
Market Dynamics
Industry Overview
The biopharmaceutical industry, particularly in the neurology and psychiatry segments, is characterized by significant unmet medical needs, high R&D costs, and a lengthy regulatory approval process. There is a growing emphasis on precision medicine and targeted therapies.
Positioning
Rapport Therapeutics is positioned as an emerging player in the precision medicine space for neurological and psychiatric disorders. Its competitive advantage lies in its focused approach to specific disease targets and its pipeline of investigational therapies.
Total Addressable Market (TAM)
The TAM for neurological and psychiatric disorders is substantial, estimated to be in the hundreds of billions of dollars globally. Rapport Therapeutics aims to capture a significant portion of specific sub-segments within these markets through its targeted therapies. Its current positioning is nascent, focusing on developing and bringing its initial pipeline products to market.
Upturn SWOT Analysis
Strengths
- Experienced management team with a track record in drug development.
- Focus on high-unmet-need areas within neurology and psychiatry.
- Proprietary drug discovery and development platform.
- Potential for novel mechanisms of action in its pipeline.
Weaknesses
- Early-stage drug pipeline with significant clinical and regulatory risks.
- Limited financial resources compared to established pharmaceutical companies.
- Dependence on successful clinical trial outcomes.
- Lack of approved products currently generating revenue.
Opportunities
- Growing demand for effective treatments for neurological and psychiatric diseases.
- Potential for strategic partnerships and collaborations.
- Advancements in genetic and molecular diagnostics to identify patient populations.
- Opportunities for orphan drug designations and accelerated pathways.
Threats
- Failure of clinical trials to demonstrate efficacy or safety.
- Intense competition from established pharmaceutical companies and other biotech firms.
- Stringent regulatory hurdles and approval processes.
- Patent expirations and generic competition for related therapies.
- Economic downturns impacting R&D funding and investment.
Competitors and Market Share
Key Competitors
- Acadia Pharmaceuticals Inc. (ACAD)
- Biogen Inc. (BIIB)
- Pfizer Inc. (PFE)
- Eli Lilly and Company (LLY)
Competitive Landscape
Rapport Therapeutics operates in a highly competitive landscape dominated by large pharmaceutical companies with extensive pipelines and significant market presence. Rapport's advantages lie in its specific focus and potential for breakthrough therapies, while its disadvantages include its smaller scale, limited resources, and the inherent risks of drug development.
Growth Trajectory and Initiatives
Historical Growth: Historically, growth has been driven by scientific advancement, securing funding (including venture capital and the recent IPO), and progress in preclinical and early-stage clinical development.
Future Projections: Future projections are highly dependent on the success of its drug candidates in clinical trials and subsequent regulatory approvals. Analyst estimates would focus on potential peak sales of its pipeline drugs if approved.
Recent Initiatives: Successful completion of its Initial Public Offering (IPO) to fund further development.,Advancement of lead drug candidates into clinical trials.,Expansion of its research and development team.,Exploration of strategic collaborations.
Summary
Rapport Therapeutics, Inc. is an emerging biotechnology company with a strong scientific foundation in developing novel treatments for neurological and psychiatric disorders. Its current focus is on advancing its pipeline through clinical trials, a process inherently fraught with risk but offering substantial reward. The company's success hinges on its ability to demonstrate the efficacy and safety of its drug candidates, navigate regulatory pathways, and secure continued funding in a competitive market.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q)
- Company Investor Relations
- Financial News Outlets (e.g., Bloomberg, Reuters)
- Industry Analysis Reports
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It does not constitute investment advice. Investors should conduct their own due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Rapport Therapeutics, Inc. Common Stock
Exchange NASDAQ | Headquaters Boston, MA, United States | ||
IPO Launch date 2024-06-07 | CEO, President, Treasurer & Director Mr. Abraham N. Ceesay M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 69 | Website https://www.rapportrx.com |
Full time employees 69 | Website https://www.rapportrx.com | ||
Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. Its lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder. The company also develops RAP-199, a TARPy8 targeted molecule with differentiated chemical and pharmacokinetic properties; and nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and a9a10 nAChR for the treatment of hearing disorders. The company was formerly known as Precision Neuroscience NewCo, Inc. and changed its name to Rapport Therapeutics, Inc. in October 2022. Rapport Therapeutics, Inc. was incorporated in 2022 and is based in Boston, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.